CAR-T Meeting 2025 | The European CAR-T Meeting 2025: balancing clinical and preclinical topics
Raffaella Greco, MD, PhD, San Raffaele Hospital, Milan, Italy, highlights the importance of the EHA-EBMT European CAR T-Cell Meeting, which balances clinical and preclinical topics and features a wide range of oral sessions covering various CAR-T aspects. The meeting also explores new indications for CAR T-cell therapy, including solid tumors and autoimmune diseases. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting, held in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
I think that for this year the CAR-T meeting is really special because we are trying to focus with a great balance between clinical and preclinical topics. Also, there is a nurse track and I think there are also a lot of interesting oral sessions, both coming from the clinic and preclinical areas, that are trying really to cover from the beginning the type of CAR-T, the construct, the markers, the costimulatory domain, the antigens, and also some biological findings together with coupling the clinical indications, so the most common ones coming from the hematology field, but also new indications like solid tumor, autoimmune disease, and also some new products coming in the different areas of application...
I think that for this year the CAR-T meeting is really special because we are trying to focus with a great balance between clinical and preclinical topics. Also, there is a nurse track and I think there are also a lot of interesting oral sessions, both coming from the clinic and preclinical areas, that are trying really to cover from the beginning the type of CAR-T, the construct, the markers, the costimulatory domain, the antigens, and also some biological findings together with coupling the clinical indications, so the most common ones coming from the hematology field, but also new indications like solid tumor, autoimmune disease, and also some new products coming in the different areas of application.
I think it’s also interesting to have a lot of interesting talks regarding the potential complications coming after CAR-T. So, for example, the secondary malignancy, that is really a big topic in this period, cardiac complications and late effects and so on, because it’s really important to see time by time that we are experiencing more knowledge on CAR-T cell application and this is also well done during the meeting with different talks.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
RG is the secretary of the EBMT.
